Quest Diagnostics Incorporated DGX

Revenue growth is driven by SG&A spending, which the log-log model shows with a positive elasticity of 0.26% in revenue for every 1% increase in SG&A (R&D data not available). Recent quarterly revenue was about $2.806 billion, and holdout testing predicted $2.8B versus actual $2.8B (0.3% error) with a model MAPE of 3.2%, underscoring forecast reliability in the near term. The ROI on SG&A investments appears modest, as a 1% SG&A increase yields only about 0.26% additional revenue, making margin gains from efficiency and targeted spending critical to creating value. The FY revenue forecast is about $11B, a +0.3% YoY change, signaling a stable, low-growth outlook where disciplined SG&A management and efficiency improvements will drive profitability alongside the steady top line.